View in EDS

The Distribution of Methicillin‐Resistant Staphylococcus aureus and Carbapenem‐Resistant Pseudomonas aeruginosa in the Academic Complex Central Hospital in KwaZulu‐Natal, South Africa: A 5‐Year Retrospective Study From 2019 to 2023

Saved in:
Bibliographic Details
Title: The Distribution of Methicillin‐Resistant Staphylococcus aureus and Carbapenem‐Resistant Pseudomonas aeruginosa in the Academic Complex Central Hospital in KwaZulu‐Natal, South Africa: A 5‐Year Retrospective Study From 2019 to 2023
Authors: Rexe, N., Kajee, A., Singh, R., Swe Swe-Han, K., Flora, Swaran J. S.
Source: International Journal of Microbiology; 10/19/2025, Vol. 2025, p1-8, 8p
Subject Terms: METHICILLIN-resistant staphylococcus aureus, CARBAPENEM-resistant bacteria, DRUG resistance, INFECTION prevention, PUBLIC health surveillance, DISEASE prevalence
Geographic Terms: SOUTH Africa
Abstract: Background: Drug‐resistant pathogens are a global health concern. Of particular concern are methicillin‐resistant Staphylococcus aureus (MRSA) and carbapenem‐resistant Pseudomonas aeruginosa (CRPA), as they leave clinicians with limited treatment options. Aim: This study was aimed at determining the prevalence of MRSA and CRPA at an academic referral hospital in KwaZulu‐Natal from January 2019 to December 2023. Method: The hospital laboratory information system provided the antimicrobial susceptibility profiles of S. aureus and P. aeruginosa. Statistical Package for the Social Sciences (SPSS, Version 21) was used to analyze data on the prevalence of MRSA and CRPA in the hospital over the past 5 years. Results: This study identified 18% (249/1,409) prevalence of MRSA in 2019 to 18% (237/1,284) by 2023. Also, the prevalence of CRPA decreased from 15% (98/673) in 2019 to 14% (85/618) by 2023. MRSA isolates in this study exhibited over 50% resistance to gentamicin, erythromycin/azithromycin, clindamycin, and trimethoprim–sulfamethoxazole. All the tested antibiotics (amikacin, cefepime, ceftazidime, ciprofloxacin, gentamicin, and piperacillin–tazobactam) against CRPA have been met by resistance of greater than 30%, except for 3% resistance to colistin. There was no statistically significant difference between females and males (p = 0.135) and between intensive care unit (ICU) and non‐ICU wards (p = 0.156). Conclusion: The growing threat of MRSA and CRPA in hospitals highlights the need for continuous surveillance to track their spread and strengthen infection prevention efforts. [ABSTRACT FROM AUTHOR]
Copyright of International Journal of Microbiology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Complementary Index
Description
Abstract:Background: Drug‐resistant pathogens are a global health concern. Of particular concern are methicillin‐resistant Staphylococcus aureus (MRSA) and carbapenem‐resistant Pseudomonas aeruginosa (CRPA), as they leave clinicians with limited treatment options. Aim: This study was aimed at determining the prevalence of MRSA and CRPA at an academic referral hospital in KwaZulu‐Natal from January 2019 to December 2023. Method: The hospital laboratory information system provided the antimicrobial susceptibility profiles of S. aureus and P. aeruginosa. Statistical Package for the Social Sciences (SPSS, Version 21) was used to analyze data on the prevalence of MRSA and CRPA in the hospital over the past 5 years. Results: This study identified 18% (249/1,409) prevalence of MRSA in 2019 to 18% (237/1,284) by 2023. Also, the prevalence of CRPA decreased from 15% (98/673) in 2019 to 14% (85/618) by 2023. MRSA isolates in this study exhibited over 50% resistance to gentamicin, erythromycin/azithromycin, clindamycin, and trimethoprim–sulfamethoxazole. All the tested antibiotics (amikacin, cefepime, ceftazidime, ciprofloxacin, gentamicin, and piperacillin–tazobactam) against CRPA have been met by resistance of greater than 30%, except for 3% resistance to colistin. There was no statistically significant difference between females and males (p = 0.135) and between intensive care unit (ICU) and non‐ICU wards (p = 0.156). Conclusion: The growing threat of MRSA and CRPA in hospitals highlights the need for continuous surveillance to track their spread and strengthen infection prevention efforts. [ABSTRACT FROM AUTHOR]
ISSN:1687918X
DOI:10.1155/ijm/6364811